Rituximab Neoadjuvant Therapy in Patients With Prostate Cancer Scheduled to Undergo Radical Prostatectomy
Status:
Unknown status
Trial end date:
2019-04-01
Target enrollment:
Participant gender:
Summary
There is now substantial evidence that B cells are recruited into prostate cancers by CXCL13
released by the tumor cells. B cells release lymphotoxin which drives malignant cell
proliferation through the NFkB pathway. This is a pilot trial in 18 patients to determine
whether depletion of B cells by rituximab will result in a decrease in the extent of B cell
infiltration of the prostatic cancer. The extent of infiltration in the diagnostic biopsy
will be compared to that in the prostatectomy samples following administration of 4 weekly
doses of rituximab.